🇺🇸 FDA

Intelligence Platform

Patents

Browse 106 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11504389

Tau modulators and methods and compositions for delivery thereof

Sangamo Therapeutics, Inc. · Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11492643

Methods and compositions for treatment of a genetic condition

Sangamo Therapeutics, Inc. · Granted Tue Nov 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11452782

Liver-specific constructs factor VIII expression cassettes and methods of use thereof

Sangamo Therapeutics, Inc. · Granted Tue Sep 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11439666

Targeted disruption of T cell receptor genes using engineered zinc finger protein nuclease

Sangamo Therapeutics, Inc. · Granted Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11421007

Zinc finger protein compositions for modulation of huntingtin (Htt)

Sangamo Therapeutics, Inc. · Granted Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11401512

Engineered target specific nucleases

Sangamo Therapeutics, Inc. · Granted Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11352631

Targeted disruption of the T cell receptor

Sangamo Therapeutics, Inc. · Granted Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11311574

Methods and compositions for targeted cleavage and recombination

Sangamo Therapeutics, Inc. · Granted Tue Apr 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11285175

Targeted disruption of the MHC cell receptor

Sangamo Therapeutics, Inc. · Granted Tue Mar 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11235026

Methods and compositions for modulating PD1

Sangamo Therapeutics, Inc. · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11236175

T cell modifying compounds and uses thereof

Sangamo Therapeutics, Inc. · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11219695

Methods and compositions for the treatment of Fabry disease

Sangamo Therapeutics, Inc. · Granted Tue Jan 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11149321

Methods and compositions for targeted single-stranded cleavage and targeted integration

Sangamo Therapeutics, Inc. · Granted Tue Oct 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11123443

Htt repressors and uses thereof

Sangamo Therapeutics, Inc. · Granted Tue Sep 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11110154

Methods and compositions for treating Huntington's Disease

Sangamo Therapeutics, Inc. · Granted Tue Sep 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11040115

Method for the treatment of lysosomal storage diseases

Sangamo Therapeutics, Inc. · Granted Tue Jun 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11041174

Compositions for linking DNA-binding domains and cleavage domains

Sangamo Therapeutics, Inc. · Granted Tue Jun 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11021696

Nuclease-mediated regulation of gene expression

Sangamo Therapeutics, Inc. · Granted Tue Jun 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11020492

Gene correction of SCID-related genes in hematopoietic stem and progenitor cells

Sangamo Therapeutics, Inc. · Granted Tue Jun 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10975393

Engineered target specific nucleases

Sangamo Therapeutics, Inc. · Granted Tue Apr 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10975375

Methods and compositions for regulation of transgene expression

Sangamo Therapeutics, Inc. · Granted Tue Apr 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10968261

Methods and compositions for genome engineering

Sangamo Therapeutics, Inc. · Granted Tue Apr 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10960085

Modulation of liver genes

Sangamo Therapeutics, Inc. · Granted Tue Mar 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10918668

Targeted disruption of T cell receptor genes using engineered zinc finger protein nuclease

Sangamo Therapeutics, Inc. · Granted Tue Feb 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted